首页> 外文期刊>Dalton transactions: An international journal of inorganic chemistry >Salt metathesis versus protonolysis routes for the synthesis of silylamide Hauser base (R2NMgX; X = halogen) and amido-Grignard (R2NMgR) complexes
【24h】

Salt metathesis versus protonolysis routes for the synthesis of silylamide Hauser base (R2NMgX; X = halogen) and amido-Grignard (R2NMgR) complexes

机译:合成硅甲酰胺Hauser碱(R2NMgX; X =卤素)和酰胺基格纳德(R2NMgR)配合物的盐复分解与质子分解途径

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The preparation of silylamide Hauser base (R2NMgX; X = halide) and amido-Grignard (R2NMgR) complexes from simple Grignard reagents using [K{N((SiMe2Bu)-Bu-t)(2)}](n), [K{N((SiMe2Bu)-Bu-t)((SiPr3)-Pr-i)}](n) and[ K{N((SiPr3)-Pr-i)(2)}](n), and their parent silylamines, was explored. Both salt metathesis and protonolysis routes proved ineffective with allylmagnesium chloride as a starting material due to complex Schlenk equilibria, with [Mg(N-RR')(mu-Cl)-(THF)](2) (N-RR' = {N((SiBuMe2)-Bu-t)(2)}(-), 1; {N(S(i)tBuMe(2))((SiPr3)-Pr-i)}(-), 2; {N((SiPr3)-Pr-i)(2)}(-), 3) and [Mg{N((SiPr3)-Pr-i)(2)}(mu-C3H5)](infinity) (4) identified as minor products. In contrast, salt metathesis protocols using potassium silylamides and methylmagnesium iodide gave[ Mg(N-RR')(mu-CH3)](2) (N-RR' = {N((SiBuMe2)-Bu-t)(2)}(-), 7a; {N((SiBuMe2)-Bu-t)((SiPr3)-Pr-i)}(-), 8; {N((SiPr3)-Pr-i)(2)}(-), 9) and[ Mg{N((SiBuMe2)-Bu-t)(2)}(CH3)(DME)] (7b), with[ Mg{N(SitBuMe(2))(2)}(mu-I)(THF)](2) (10) isolated as a side-product during the preparation of 7a. Unusually, methylmagnesium iodide, di-n-butylmagnesium and 7-9 did not react with HNRR' under the conditions we employed. The synthesis of [Na{N((SiBuMe2)-Bu-t)(2)}-(THF)](2) (5a) and [Na{N(SitBuMe(2))(2)}(DME)(2)] (5b) from benzyl sodium and HN((SiBuMe2)-Bu-t)(2), and a solvent-free structure of[ K{N(SitBuMe(2))(2)}] (6), are also reported. Complexes 1, 5b, 7a, 7b, 8, 9 and 10 are fully characterised by single crystal XRD, multinuclear NMR and IR spectroscopy and elemental analysis, whereas complexes 2-4, 5a and 6 were identified by XRD only.
机译:使用[K {N((SiMe2Bu)-Bu-t)(2)}](n),[K {N((SiMe2Bu)-Bu-t)((SiPr3)-Pr-i)}](n)和[K {N((SiPr3)-Pr-i)(2)}](n)及其探索了母体甲硅烷基胺。由于烯丙基氯化镁的复杂Schlenk平衡,[Mg(N-RR')(mu-Cl)-(THF)](2),盐复分解和质子分解途径均无效。 N((SiBuMe2)-Bu-t)(2)}(-),1; {N(S(i)tBuMe(2))(((SiPr3)-Pr-i)}(-),2; {N ((SiPr3)-Pr-i)(2)}(-),3)和[Mg {N((SiPr3)-Pr-i)(2)}(mu-C3H5)](无穷大)(4)已确定作为次要产品。相比之下,使用甲硅烷基氨基钾和甲基碘化镁的盐复分解方案给出了[Mg(N-RR')(mu-CH3)](2)(N-RR'= {N((SiBuMe2)-Bu-t)(2) }(-),7a; {N((SiBuMe2)-Bu-t)((SiPr3)-Pr-i)}(-),8; {N((SiPr3)-Pr-i)(2)}( -),9)和[Mg {N((SiBuMe2)-Bu-t)(2)}(CH3)(DME)](7b),以及[Mg {N(SitBuMe(2))(2)}(在制备7a时作为副产物分离出mu-I)(THF)](2)(10)。通常,在我们使用的条件下,甲基碘化镁,二正丁基镁和7-9不会与HNRR'反应。 [Na {N((SiBuMe2)-Bu-t)(2)}-(THF)](2)(5a)和[Na {N(SitBuMe(2))(2)}(DME)( 2)](5b)由苄基钠和HN((SiBuMe2)-Bu-t)(2)组成,[[K {N(SitBuMe(2))(2)}](6)为无溶剂结构,也有报道。配合物1、5b,7a,7b,8、9和10可通过单晶XRD,多核NMR和IR光谱及元素分析充分表征,而配合物2-4、5a和6仅通过XRD鉴定。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号